ArticleMMWR. Morbidity and mortality weekly report2024
Progress Toward Measles Elimination - Worldwide, 2000-2023.
Article in MMWR. Morbidity and mortality weekly report, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Uptake of the Second Dose of the Measles Vaccine and Its Determinants Among Children Aged Less Than 5 Years: Systematic Review and Meta-Analysis.JMIR public health and surveillance · 2025Pooled it
- Preliminary safety data from a randomised trial of early versus standard timing of administration of measles-rubella vaccine in Ugandan infants.Discover medicine · 2026Trial
- Immunogenicity and safety of a measles and rubella-containing vaccine at age 6 and 9 months in Bangladesh: an open-label, randomised trial.The Lancet. Child & adolescent health · 2025Trial
- Socioeconomic inequality in second-dose measles vaccination dropout among children aged 15-35 months in East Africa: A decomposition analysis of a recent Demographic Health Survey.Human vaccines & immunotherapeutics · 2026Article
- Targeted pneumococcal conjugate vaccination strategies for high-risk children.Human vaccines & immunotherapeutics · 2026Review
- Article
- Immunity gap for measles in young adults: Seroprevalence study in blood donors in southern Italy.Human vaccines & immunotherapeutics · 2026Article
- Small quantity lipid-based nutritional supplementation and measles vaccination coverage in children aged 6-23 months: a pragmatic cluster-randomized trial.Nature medicine · 2026Article
- Extracorporeal membrane oxygenation for life-threatening measles in children: a case series.European journal of pediatrics · 2026Article
- Waning Measles Immunity and Sustained Rubella Seroprotection Among Adults in Istanbul, Türkiye.Medicina (Kaunas, Lithuania) · 2026Article
- Seroprevalence of IgG Antibodies to Measles, Mumps, Rubella and Varicella in Adolescents with Documented Two-Dose MMR Vaccination: Cross-Sectional Study.Antibodies (Basel, Switzerland) · 2026Article
- Bridging the Gap: Measles Susceptibility and Neutralization Test-Confirmed Immunity in a Spanish HIV-PrEP Cohort.Open forum infectious diseases · 2026Article
- Cost of a Measles Outbreak in an Urban Shelter.JAMA network open · 2026Article
- Review
- The prevalence of measles vaccination in measles-infected healthcare workers: A systematic review and meta-analysis.Journal of infection prevention · 2026Review
- Toward a quality-managed operational architecture for wastewater surveillance of zoonotic and emerging pathogens.Applied and environmental microbiology · 2026Review
- Measles and Rubella Elimination Trends in the WHO Eastern Mediterranean Region, 2023-2024: Progress and Recent Epidemiological Shifts.Vaccines · 2026Article
- Measles outbreaks in Nepal: sustaining rapid response through equity-focused immunization and surveillance.Annals of medicine and surgery (2012) · 2026Article
- COVID-19-related disruptions and measles vaccination uptake among children attending urban health centers in Guelmim, Morocco: a cross-sectional study.BMC public health · 2026Article
- Measles Epidemiology, Transmission, and Surveillance Characteristics in Ethiopia, 2018-2024.Journal of epidemiology and global health · 2026Article
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Measles vaccination effectively prevents measles, a highly contagious disease that can cause severe complications and death and requires high population immunity to interrupt transmission. This report describes measles elimination progress during 2000-2023. During 2000-2023, an estimated 60.3 million measles deaths were averted by vaccination. However, despite commitment from all six World Health Organization regions to eliminate measles, no region has successfully achieved and maintained measles elimination as of the end of 2023. During the COVID-19 pandemic, estimated global coverage with the first dose of measles-containing vaccine (MCV1) declined to 81%, the lowest level since 2008. MCV1 coverage improved to 83% in 2022 but was unchanged in 2023. From 2022 to 2023, estimated measles cases increased 20% worldwide, from 8,645,000 to 10,341,000; the number of countries experiencing large or disruptive outbreaks increased from 36 to 57. Estimated measles deaths decreased 8%, from 116,800 in 2022 to 107,500 in 2023, primarily because an increased number of cases occurred in countries with lower risk for death. The stagnation in MCV1 coverage means millions of children remain unprotected, leading to increases in cases and outbreaks. Coverage with measles-containing vaccine (MCV) is lower, and measles incidence is higher, in low-income countries and countries experiencing fragile, conflict-affected, and vulnerable settings, which exacerbate inequities. Urgent and targeted efforts are needed to ensure that all children receive 2 MCV doses and that surveillance is strengthened to hasten progress toward measles elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.